摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(4-methyl-1-piperazinyl)naphtho[2,3-d]oxazole | 159731-63-2

中文名称
——
中文别名
——
英文名称
2-(4-methyl-1-piperazinyl)naphtho[2,3-d]oxazole
英文别名
2-(4-methylpiperazin-1-yl)benzo[f][1,3]benzoxazole
2-(4-methyl-1-piperazinyl)naphtho[2,3-d]oxazole化学式
CAS
159731-63-2
化学式
C16H17N3O
mdl
——
分子量
267.33
InChiKey
OMPFUJFCCNRVKS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    20
  • 可旋转键数:
    1
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.31
  • 拓扑面积:
    32.5
  • 氢给体数:
    0
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    2-(4-methyl-1-piperazinyl)naphtho[2,3-d]oxazole丙烯酰碘 在 ice 、 乙酸乙酯 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 2.5h, 以to obtain 28 mg of the title compound的产率得到1-Allyl-1-methyl-4-(naphtho[2,3-d]oxazol-2-yl)piperazinium iodide
    参考文献:
    名称:
    Benzoxazole derivatives
    摘要:
    公式(1)或(2)的苯并噁唑衍生物,在2-位置具有脂环型二胺基团:##STR1## 其中R.sup.1,R.sup.2,R.sup.3,R.sup.4,R.sup.5,R.sup.6,X.sup.-,m和n在此定义。该化合物表现出优异的5-HT.sub.3受体拮抗作用,可用作止吐剂、控制肠蠕动剂、镇痛剂、抗焦虑剂和治疗精神分裂症的药物。
    公开号:
    US05631257A1
  • 作为产物:
    描述:
    3H-1-oxa-3-aza-cyclopenta[b]naphthalene-2-thione五氯化磷N-甲基哌嗪 在 ice 、 乙酸乙酯 、 silica gel 、 氯仿甲醇 作用下, 以 为溶剂, 反应 53.5h, 以to obtain 18 mg of the title compound的产率得到2-(4-methyl-1-piperazinyl)naphtho[2,3-d]oxazole
    参考文献:
    名称:
    Benzoxazole derivatives
    摘要:
    公式(1)或(2)的苯并噁唑衍生物,在2-位置具有脂环型二胺基团:##STR1## 其中R.sup.1,R.sup.2,R.sup.3,R.sup.4,R.sup.5,R.sup.6,X.sup.-,m和n在此定义。该化合物表现出优异的5-HT.sub.3受体拮抗作用,可用作止吐剂、控制肠蠕动剂、镇痛剂、抗焦虑剂和治疗精神分裂症的药物。
    公开号:
    US05631257A1
点击查看最新优质反应信息

文献信息

  • Serotonin 5-HT, receptor partial activator
    申请人:——
    公开号:US20010016579A1
    公开(公告)日:2001-08-23
    This invention provides a serotonin 5-HT 3 receptor partial activator which has a serotonin 5-HT 3 receptor activating action, in addition to its serotonin 5-HT 3 receptor antagonism, and does not cause constipation as a side effect. Particularly, based on the finding that newly synthesized benzoxazole derivatives typified by the compounds of the following formula (2) have strong serotonin 5-HT 3 receptor antagonism and serotonin 5-HT 3 receptor activating action, this invention provides these benzoxazole derivatives as serotonin 5-HT 3 receptor partial activators. 1 In the above formula, R 1 to R 4 may be the same or different from one another and each represents a hydrogen atom, a halogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted lower alkenyl group or a substituted or unsubstituted amino group, or two groups of R 1 and R 2 may be linked together to form a ring structure, namely benzene ring; R 5 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group or a substituted or unsubstituted lower alkenyl group; and m is an integer of 1 to 4.
    本发明提供了一种5-HT3受体部分激动剂,该激动剂具有5-HT3受体激活作用,除了其5-HT3受体拮抗作用外,不会引起便秘等副作用。特别是,基于新合成的苯并咪唑衍生物发现,该衍生物以以下式子(2)的化合物为代表具有强烈的5-HT3受体拮抗作用和5-HT3受体激活作用,本发明提供这些苯并咪唑衍生物作为5-HT3受体部分激动剂。在上述公式中,R1到R4可以相同也可以不同,每个表示氢原子、卤素原子、取代或未取代的低级烷基、取代或未取代的低级烯基或取代或未取代的氨基;或R1和R2的两个基团可以连接在一起形成环结构,即苯环;R5表示氢原子、取代或未取代的低级烷基或取代或未取代的低级烯基;m是1到4的整数。
  • Serotonin 5-HT3 receptor partial activator
    申请人:MEIJI SEIKA KAISHA, LTD.
    公开号:US20030013730A1
    公开(公告)日:2003-01-16
    This invention provides a serotonin 5-HT 3 receptor partial activator which has a serotonin 5-HT 3 receptor activating action, in addition to its serotonin 5-HT 3 receptor antagonism, and does not cause constipation as a side effect. Particularly, based on the finding that newly synthesized benzoxazole derivatives typified by the compounds of the following formula (2) have strong serotonin 5-HT 3 receptor antagonism and serotonin 5-HT 3 receptor activating action, this invention provides these benzoxazole derivatives as serotonin 5-HT 3 receptor partial activators. 1 In the above formula, R 1 to R 4 may be the same or different from one another and each represents a hydrogen atom, a halogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted lower alkenyl group or a substituted or unsubstituted amino group, or two groups of R 1 and R 2 may be linked together to form a ring structure, namely benzene ring; R 5 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group or a substituted or unsubstituted lower alkenyl group; and m is an integer of 1 to 4.
    该发明提供了一种5-HT3受体部分激动剂,具有5-HT3受体激活作用,除了5-HT3受体拮抗作用外,不会引起便秘等副作用。特别地,基于新合成的苯并噁唑衍生物的发现,该衍生物以以下公式(2)的化合物为代表,具有强烈的5-HT3受体拮抗作用和5-HT3受体激活作用,该发明提供这些苯并噁唑衍生物作为5-HT3受体部分激动剂。在上述公式中,R1至R4可以相同或不同,每个代表氢原子、卤素原子、取代或未取代的低级烷基、取代或未取代的低级烯基或取代或未取代的氨基,或R1和R2的两个基团可以连接在一起形成环结构,即苯环;R5代表氢原子、取代或未取代的低级烷基或取代或未取代的低级烯基;m是1到4的整数。
  • Benzoxazole derivatives and their use as serotonin 5-HT3 receptor antagonists
    申请人:MEIJI SEIKA KAISHA LTD.
    公开号:EP0621271A1
    公开(公告)日:1994-10-26
    A benzoxazole derivative of the formula (1) or (2) which has an alicyclic diamine group at the 2-position: wherein R¹, R², R³ and R⁴ may be the same or different and each represents hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, halogen, hydroxyl, amino, lower alkoxy, carboxyl, carbamoyl and nitro, or any two of R¹ to R⁴ may be linked together to form a three to seven-membered ring structure comprising carbon atoms alone or carbon atoms and 1 to 2 hetero atoms, which may be substituted; R⁵ and R⁶ may be the same or different and each represents substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted aralkyl group or an alkoxycarbonyl group, or R⁵ and R⁶ may be linked together to form a three to seven-membered ring structure comprising carbon atoms and 1 to 2 nitrogen atoms, which may be substituted; X⁻ is a pharmaceutically acceptable anion; and m and n may be the same or different and each is an integer of 1 to 3. The compound shows excellent 5-HT₃ receptor antagonism and is useful as an antiemetic agent and also as a peristalsis controlling agent, an analgesic agent, an antianxiety agent and a schizophrenia treating agent.
    式(1)或(2)的苯并恶唑衍生物,其 2 位上有脂环二胺基团: 其中 R¹、R²、R³ 和 R⁴ 可以相同或不同,各自代表氢、取代或未取代的低级烷基、取代或未取代的低级烯基、卤素、羟基、氨基、低级烷氧基、羧基、氨基甲酰基和硝基,或者 R¹ 至 R⁴ 中的任意两个可以连接在一起,形成由单独的碳原子或碳原子和 1 至 2 个杂原子组成的三至七元环结构,这些杂原子可以被取代;R⁵和R⁶可以相同或不同,并且各自代表取代或未取代的低级烷基、取代或未取代的低级烯基、取代或未取代的芳烷基或烷氧基羰基,或者R⁵和R⁶可以连接在一起形成由碳原子和 1 至 2 个氮原子组成的三至七元环结构,该结构可以被取代;X- 是药学上可接受的阴离子;m 和 n 可以相同或不同,且各自为 1 至 3 的整数。该化合物具有优异的 5-HT₃ 受体拮抗作用,可用作止吐药,也可用作肠蠕动控制剂、镇痛剂、抗焦虑剂和精神分裂症治疗剂。
  • Benzoxazole derivatives as serotonin 5-HT3 receptor partial activator
    申请人:MEIJI SEIKA KAISHA LTD.
    公开号:EP0806419A1
    公开(公告)日:1997-11-12
    This invention provides a serotonin 5-HT3 receptor partial activator which has a serotonin 5-HT3 receptor activating action, in addition to its serotonin 5-HT3 receptor antagonism, and does not cause constipation as a side effect. Particularly, based on the finding that newly synthesized benzoxazole derivatives typified by the compounds of the following formula (2) have strong serotonin 5-HT3 receptor antagonism and serotonin 5-HT3 receptor activating action, this invention provides these benzoxazole derivatives as serotonin 5-HT3 receptor partial activators. In the above formula, R1 to R4 may be the same or different from one another and each represents a hydrogen atom, a halogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted lower alkenyl group or a substituted or unsubstituted amino group, or two groups of R1 and R2 may be linked together to form a ring structure, namely benzene ring; R5 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group or a substituted or unsubstituted lower alkenyl group; and m is an integer of 1 to 4.
    本发明提供了一种5-羟色胺5-HT3受体部分激活剂,它除了具有5-羟色胺5-HT3受体拮抗作用外,还具有5-羟色胺5-HT3受体激活作用,并且不会引起便秘副作用。 特别是,基于新合成的以下式(2)化合物为典型代表的苯并恶唑衍生物具有很强的血清素 5-HT3 受体拮抗作用和血清素 5-HT3 受体激活作用,本发明提供了这些苯并恶唑衍生物作为血清素 5-HT3 受体部分激活剂。 上式中,R1~R4可以相同或互不相同,各自代表氢原子、卤素原子、取代或未取代的低级烷基、取代或未取代的低级烯基或取代或未取代的氨基,也可以将R1和R2的两个基团连接在一起形成环状结构,即苯环;R5代表氢原子、取代或未取代的低级烷基或取代或未取代的低级烯基;m为1~4的整数。
  • US5631257A
    申请人:——
    公开号:US5631257A
    公开(公告)日:1997-05-20
查看更多